Flavoxine is a proprietary blend of extracts from the bark of Phellodendron amurense and a formulation of polymethoxylated flavones extracted from Citrus sinensis (US Patent Nos. 6,184,246 and 6,987,125). This distinctive combination of all-natural ingredients supports cardiovascular health and weight management.
Flavoxine works by several mechanisms. The active ingredient in Phellodendron amurense, Berberine, regulates LDL-C homeostasis. Meanwhile, the polymethoxylated flavones reduce the availability of lipid substrates for hepatic (liver) VLDL production and inhibit the production of tumor necrosis factor-alpha (TNF-alpha).
Heart disease is the leading cause of death among both men and women. Over half a million people die every year of heart disease, as millions more live with the disease every day.
Cardiovascular health has been clearly linked to inflammatory processes throughout the body. High levels of C-reactive-protein, a pro-inflammatory cytokine, is associated with high lipids and coronary artery disease. By keeping CRP and other pro-inflammatory cytokines in check, lipids are far more likely to stay in a healthy range.
A study published in 2012 examined the effects of flavonoid subclasses on the risk level of different types of stroke in women. The results suggested that flavanones from citrus fruit may be associated with a reduced risk of ischemic stroke.
In a double-blind, placebo-controlled clinical trial with 80 subjects, Flavoxine significantly reduced LDL-C by 45% in 8 weeks in the overweight subjects (p<0.001) and by 17% in the normal weight subjects (p<0.01). HDL-C was significantly increased in both the overweight and normal subjects over the same time period.
Triglycerides were significantly (p<0.05) reduced by 18% in the overweight group and by 14.5% (p<0.001) in the normal weight group. Without a change in diet or exercise, Flavoxine significantly (p<0.001) lowered weight and BMI by 5% in the overweight subjects by the end of the study. This study was published in Nutrition Journal 2008, 7:16.
Flavoxine’s exclusive blend cannot be replicated. It is like no other cardiovascular support product on the market and is a must for cardiovascular care. Flavoxine is produced in the US at a cGMP facility.